Li et al., 2024 - Google Patents
Canine distemper virus (CDV)-neutralizing activities of an anti-CDV canine-derived single-chain variable antibody fragment 4-15 (scFv 4-15) screened by phage …Li et al., 2024
- Document ID
- 706694323839796061
- Author
- Li Y
- Song J
- Jiang S
- Yang Y
- Han Y
- Zhong L
- Zhou J
- Wang M
- Song H
- Xu Y
- Publication year
- Publication venue
- International Journal of Biological Macromolecules
External Links
Snippet
Canine distemper virus (CDV) is a highly contagious pathogen that causes severe diarrhea, fever and vomiting in domestic dogs, posing a serious threat to the dog breeding industry. Currently, there are no effective therapeutic agents for emergency treatment despite the …
- 241000712083 Canine morbillivirus 0 title abstract description 141
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Somasundaram et al. | An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review | |
| TWI628190B (en) | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof | |
| CN103476929B (en) | Resisiting influenza virus neutralizing antibody and its screening technique | |
| RU2764740C1 (en) | Bispecific antibody against rabies virus and its application | |
| CN118063603A (en) | Anti-B botulinum toxin neutralizing antibodies and related biomaterials and uses thereof | |
| Li et al. | Canine distemper virus (CDV)-neutralizing activities of an anti-CDV canine-derived single-chain variable antibody fragment 4-15 (scFv 4-15) screened by phage display technology | |
| Salem et al. | Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein | |
| CN113416249B (en) | Compositions against tetanus toxin | |
| CN119462909A (en) | Monoclonal antibody targeting coronavirus and its application and preparation method | |
| WO2022036337A1 (en) | Compositions and methods for recombinant polypeptide mimicking sars-cov-2 nucleocapsid protein (np) | |
| WO2023279803A1 (en) | Protein binding molecule of rbv and use thereof | |
| CN115260306B (en) | Monoclonal antibodies targeting SARS-CoV-2 receptor binding motifs and their recognized antigen epitopes and applications | |
| Guo et al. | Screening scFv antibodies against infectious bursal disease virus by co-expression of antigen and antibody in the bacteria display system | |
| Pavan et al. | Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants | |
| Zheng et al. | Vaccine molecule design based on phage display and computational modeling against rhabdovirus | |
| CN114539394B (en) | SARS-CoV-2 alpha mutant and beta mutant camelid-derived high affinity nanobody | |
| Duan et al. | Human monoclonal Fab antibodies against West Nile virus and its neutralizing activity analyzed in vitro and in vivo | |
| Xiao et al. | Development of a potent neutralizing nanobody against canine distemper virus hemagglutinin protein | |
| CN117756934B (en) | Anti-tetanus nanobody or antigen binding fragment thereof, and related biological material and application thereof | |
| Lin et al. | A platform for the rapid screening of equine immunoglobins F (ab) 2 derived from single equine memory B cells able to cross-neutralize to influenza virus | |
| WO2019227039A1 (en) | Compositions comprising antibodies to rabies virus and the uses thereof | |
| RU2815280C1 (en) | Tetanus toxin antibody and use thereof | |
| US20240285753A1 (en) | Epitope-scaffold immunogens for pancoronavirus vaccines | |
| CN103848915A (en) | Preparation and application of novel anti-rabies virus glycoprotein human-derived genetically-engineered antibody | |
| WO2013185193A1 (en) | Method for producing and obtaining variable domains of anti-digoxin monoclonal antibody fab fragment using the molecular biology cloning technique |